Home » Stocks » AGRX

Agile Therapeutics, Inc. (AGRX)

Stock Price: $1.82 USD -0.02 (-1.09%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $1.78 -0.04 (-2.20%) Apr 16, 6:40 PM
Market Cap 159.48M
Revenue (ttm) 749,000
Net Income (ttm) -51.85M
Shares Out 84.68M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $1.82
Previous Close $1.84
Change ($) -0.02
Change (%) -1.09%
Day's Open 1.83
Day's Range 1.75 - 1.86
Day's Volume 1,377,700
52-Week Range 1.75 - 3.89

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.

Other stocks mentioned: CMPI, CYTH, GORO, RYTM, WINT, WMPN
1 week ago - InvestorPlace

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

Other stocks mentioned: AQMS, CATB, CKPT, HEPA, IFRX, LLNW
2 weeks ago - InvestorPlace

PRINCETON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will pres...

1 month ago - GlobeNewsWire

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 13.04% and -25.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially available

1 month ago - GlobeNewsWire

PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will participat...

3 months ago - GlobeNewsWire

PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company will present at the 39th Annual J.P. Morgan Healthca...

3 months ago - GlobeNewsWire

Agile Therapeutics is preparing to launch their first FDA approved product, Twirla. If all goes well, Twirla could quickly establish a foothold in a $4.1B addressable market. Launching an FDA approved p...

4 months ago - Seeking Alpha

Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE)

4 months ago - GlobeNewsWire

PRINCETON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception, an international, peer-reviewed, reproductiv...

4 months ago - GlobeNewsWire

PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will par...

4 months ago - GlobeNewsWire

The drugmaker will soon give Twirla a twirl.

5 months ago - The Motley Fool

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Commercial Launch of Twirla® Expected by Year-End 2020

5 months ago - GlobeNewsWire

PRINCETON, N.J., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be virtually presentin...

6 months ago - GlobeNewsWire

PRINCETON, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executi...

7 months ago - GlobeNewsWire

Company to Present Twirla® Commercial Plan

7 months ago - GlobeNewsWire

Visit BirthControlDoneMyWay.com to learn more about some of the many available contraceptive options

7 months ago - GlobeNewsWire

PRINCETON, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced the appointment of Paul Korner, MD, MBA, to t...

8 months ago - GlobeNewsWire

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

PRINCETON, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will p...

8 months ago - GlobeNewsWire

Agile Therapeutics (AGRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

9 months ago - Zacks Investment Research

PRINCETON, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the Company will be added to the Russell 3000® and 2000® ...

10 months ago - GlobeNewsWire

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

Agile's shares are heating up ahead of the company's Q1 earnings report.

11 months ago - The Motley Fool

Agile Therapeutics: Billion Dollar Buy-Out Is On The Horizon

11 months ago - Seeking Alpha

PRINCETON, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the company has nominated Sharon Barbar...

11 months ago - GlobeNewsWire

Agile Therapeutics (AGRX) closed at $1.86 in the latest trading session, marking no change from the prior day.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

The biotech stock is getting hit hard by the marketwide downturn today. Here's why.

1 year ago - The Motley Fool

Agile's stock can't seem to find a bottom, despite a major regulatory approval earlier this month.

1 year ago - The Motley Fool

Shares drop after the company releases the pricing details of a recently announced capital raise.

1 year ago - The Motley Fool

Agile Therapeutics (AGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Is (AGRX) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

PRINCETON, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15 million ...

1 year ago - GlobeNewsWire

PRINCETON, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock i...

1 year ago - GlobeNewsWire

Twirla now has a green light from the FDA. And that could mean a green light for investors looking for a promising small-cap biotech stock.

1 year ago - The Motley Fool

Agile Therapeutics Inc. (NASDAQ: AGRX) shares took a dip on Tuesday after the company announced a key U.S.

1 year ago - 24/7 Wall Street

Agile Could Reach $10/Share After Twirla Approval

Other stocks mentioned: MDCO
1 year ago - Seeking Alpha

Coronavirus is having a major impact across sectors.

1 year ago - Seeking Alpha

Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S.

1 year ago - GlobeNewsWire

The drugmaker is borrowing money to tide it over until it can hopefully achieve commercial success for its first product.

1 year ago - The Motley Fool

Bargain-seeking investors might want to look at these three stocks before venturing into the risky world of penny stocks.

Other stocks mentioned: SAN
1 year ago - The Motley Fool

Funding to Support the Company’s Commercialization Plans for Twirla ®

1 year ago - GlobeNewsWire

Short-Term Catalyst And Long-Term M&A Potential Make Agile Therapeutics An Attractive Potential Takeover Target

1 year ago - Seeking Alpha

From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs its reviewing this month.

Other stocks mentioned: ABBV, AMRN, ESPR, LLY, MRK
1 year ago - The Motley Fool

About AGRX

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a reg... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
May 23, 2014
CEO
Alfred Altomari
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
AGRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for AGRX stock is "Buy." The 12-month stock price forecast is 8.25, which is an increase of 353.30% from the latest price.

Price Target
$8.25
(353.30% upside)
Analyst Consensus: Buy